Cellectar Biosciences (CLRB) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 70.7% versus a loss of 97.3%. Over five years, CLRB leads with a -99.5% price change compared with -99.8% for TVRD. Tvardi Therapeutics is the larger company by market cap ($14.4 million vs $13.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | TVRD |
|---|---|---|
| Share price | $1.40 | $1.08 |
| Market cap | $13.23M | $14.41M |
| 1-day change | -7.28% | -1.82% |
| YTD return | -52.54% | -74.88% |
| 1-year return | -70.71% | -97.29% |
| 5-year return | -99.49% | -99.77% |
| EPS (TTM) | $-3.46 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $43.65 |
| 52-week low | $1.34 | $0.93 |
| Distance from 52-week high | -72.39% | -97.53% |
| Analyst consensus | none | buy |
| Avg. price target upside | +721.43% | +756.48% |
| Average volume | 63.86K | 424.45K |
| Shares outstanding | 9.45M | 13.34M |
| Employees | 11 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLRB has outperformed TVRD by 26.6 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Healthcare · Biotechnology · 11 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Healthcare · Biotechnology · 12 employees
CLRB vs TVRD FAQ
Which is bigger, Cellectar Biosciences or Tvardi Therapeutics?
Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $14.41M compared with $13.23M for Cellectar Biosciences (CLRB).
Which stock has performed better over the past year, CLRB or TVRD?
CLRB returned -70.71% over the past 12 months, compared with -97.29% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.